当前位置： SCI文献检索 > JOURNAL OF CATARACT AND REFRACTIVE SURGERY期刊下所有文献 > Tolerability and toxicity of topically applied nepafenac 0.3% compared with generic ketorolac 0.5.

Tolerability and toxicity of topically applied nepafenac 0.3% compared with generic ketorolac 0.5.

Abstract：

PURPOSE:To compare patient-reported tolerability, impact on quality of life, interference with activities of daily life, and ocular surface toxicity of branded nepafenac 0.3% and generic ketorolac 0.5% after cataract surgery. SETTING:Harvard Eye Associates, Laguna Hills, California, and the Cincinnati Eye Institute, Ohio, USA. DESIGN:Prospective case series. METHODS:One eye of each patient was randomized to receive ketorolac 0.5% or nepafenac 0.3% topical eyedrops for 3 days preoperatively and 28 days postoperatively. Additional medications were moxifloxacin 0.5% 4 times a day 3 days preoperatively and 7 days postoperatively and difluprednate 0.05% twice a day for 1 week postoperatively. Primary endpoints were patient-reported tolerability of each drug, the related impact on quality of life, and activities of daily life. Secondary endpoints were differences in conjunctival hyperemia, anterior chamber inflammation, tear breakup time (TBUT), and corneal staining. RESULTS:Baseline characteristics were similar between the nepafenac group (n = 91) and the ketorolac group (n = 90). Burning and stinging lasted longer in the ketorolac group, while blurry/hazy/foggy vision and a film or coating on the eye lasted longer in the nepafenac group (all P < .0001). All objective measures were statistically significant for ketorolac 0.5% versus nepafenac 0.3% as follows: corneal staining (64% versus 28%); Oxford grade 2 or greater staining (28% versus 4%); Schulze grade 30 or greater conjunctival erythema (65% versus 36%, respectively); abnormal TBUT greater than 10 seconds (77% versus 51%) (all P < .0001). CONCLUSION:Branded nepafenac 0.3%-treated patients had significantly better objective and subjective outcomes after cataract surgery than generic ketorolac 0.5%-treated patients.

journal_name

J Cataract Refract Surg

journal_title

Journal of cataract and refractive surgery

authors

Hovanesian J,Holland E

doi

10.1016/j.jcrs.2018.08.039

subject

Has Abstract

pub_date

2019-02-01 00:00:00

pages

174-180

issue

eissn

0886-3350

issn

1873-4502

pii

S0886-3350(18)30862-9

journal_volume

pub_type

杂志文章,多中心研究,随机对照试验

在线工具

Tolerability and toxicity of topically applied nepafenac 0.3% compared with generic ketorolac 0.5.